Developer docs
API playgroundTry for free, no card

Search company profiles

Denali Therapeutics

Full company profile

uuid0002eut

Namestring
Denali Therapeutics
Legal namestring
Denali Therapeutics Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Denali Therapeutics is a clinical-stage and now commercial-stage biopharmaceutical company developing therapeutics that cross the blood-brain barrier to treat neurodegenerative diseases and lysosomal storage disorders. The company's proprietary TransportVehicle (TV) platform is a modular delivery technology using Transferrin Receptor targeting to deliver large molecule biotherapeutics — including enzymes, oligonucleotides, and antibodies — to the brain following systemic administration, achieving 10-30x greater brain exposure than conventional methods. In March 2026, the FDA granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier, for the treatment of neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. The company's pipeline extends the TV platform across multiple franchises, including DNL126 (Sanfilippo syndrome type A), DNL952 (Pompe disease), DNL593 (frontotemporal dementia), and DNL628 (Alzheimer's disease).

Denali's business model centers on commercial sales of AVLAYAH priced at $5,200 per 150mg vial with annual treatment costs of $270,000-$811,000 depending on patient weight — a ~60% premium over the Elaprase standard of care. The company targets an addressable population of approximately 400-500 US patients and ~2,000 globally, distributed through specialty pharmacies with patient support services. Non-dilutive capital sources include a $275M synthetic royalty agreement with Royalty Pharma (9.25% royalty on worldwide net sales) and a $195M sale of a Rare Pediatric Disease Priority Review Voucher. Equity financing has included a $500M private placement in February 2024 and a $200M public offering in December 2025, bringing cash and equivalents to approximately $1.05-1.17 billion.

Denali is headquartered in South San Francisco, California, with additional offices in Salt Lake City, Utah (manufacturing) and Zurich, Switzerland. The company is publicly traded on NASDAQ under the ticker DNLI with a market capitalization of approximately $4.05 billion as of June 2026, 251-500 employees, and 92.92% institutional ownership. Recent strategic setbacks include the discontinuation of BIIB122 with Biogen after the Phase 2b LUMA trial failed in idiopathic Parkinson's disease, and the termination of the DNL593 collaboration by Takeda, both of which have refocused the company on independent pipeline development.

Short descriptiontext

Denali Therapeutics is a commercial-stage biopharmaceutical company developing therapeutics that cross the blood-brain barrier using its proprietary TransportVehicle platform, serving patients with neurodegenerative diseases and lysosomal storage disorders such as Hunter syndrome.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-brain barrier delivery, enzyme replacement therapy, neurodegenerative disease therapeutics, lysosomal storage disorder treatment, biotherapeutic drug development
Industry4 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals — Neurodegenerative and Rare Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1AVLAYAH Product Sales
TypeOne Time License
Description

Revenue from commercial sales of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome. Priced at $5,200 per 150mg vial with annual costs of $270,000-$811,000 depending on patient weight. Targeting approximately 400-500 US patients and ~2,000 globally.

medcitynews.com
2Royalty Revenue
TypeLicensing Royalties
Description

Non-dilutive royalty funding arrangement with Royalty Pharma providing $275 million based on future net sales of tividenofusp alfa, with Royalty Pharma receiving 9.25% royalty on worldwide net sales

globenewswire.com
3Priority Review Voucher Sale
TypeTransaction Fee
Description

Sale of FDA Rare Pediatric Disease Priority Review Voucher earned from AVLAYAH approval for $195 million in June 2025

finance.yahoo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Per-vial pricing for AVLAYAH enzyme replacement therapy
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$5,200 per 150mg vial. Annual costs: $270,000-$811,000 depending on patient weight. Premium pricing vs. standard of care (Elaprase) at approximately 60% higher.

medcitynews.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1TransportVehicle™ (TV) Platform
Description

Proprietary platform enabling delivery of enzymes, oligonucleotides and antibodies across the blood-brain barrier

denalitherapeutics.com
+4 more records
Core offering1 text field

Denali Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes biotherapeutics capable of crossing the blood-brain barrier. Its FDA-approved product AVLAYAH (tividenofusp alfa-eknm) is an enzyme replacement therapy for the neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients, launched in March 2026 as the first FDA-approved biologic designed to cross the BBB. The company also maintains a clinical pipeline spanning Sanfilippo syndrome type A, Pompe disease, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, all built on its proprietary TransportVehicle (TV) platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 91% reduction in cerebrospinal fluid heparan sulfate levels after 24 weeks of treatment with AVLAYAH
+3 more records
Product overview1 text field

Denali Therapeutics is a biopharmaceutical company that has transitioned from R&D to commercial-stage operations with the FDA approval of AVLAYAH in March 2026. The company's core offering centers on its proprietary TransportVehicle (TV) platform, which enables biotherapeutics to cross the blood-brain barrier. The TV platform supports three franchise areas: Enzyme TransportVehicle (ETV) for lysosomal storage disorders, Oligonucleotide TransportVehicle (OTV) for CNS gene expression modulation, and Antibody TransportVehicle (ATV) for antibody delivery to the brain. The approved product AVLAYAH (tividenofusp alfa-eknm) is an enzyme replacement therapy for Hunter syndrome. The pipeline includes multiple candidates across lysosomal storage disorders, neurodegenerative diseases, and inflammatory conditions.

Product and service1 record
1AVLAYAH (tividenofusp alfa-eknm)
CategoryFDA-approved enzyme replacement therapy
Description

FDA-approved enzyme replacement therapy for the neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. AVLAYAH uses Denali's proprietary TransportVehicle technology to cross the blood-brain barrier, addressing CNS symptoms that previous enzyme replacement therapies like Elaprase cannot treat. Priced at $5,200 per 150mg vial with annual costs of $270,000–$811,000 depending on patient weight.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-01
Description

Partnership formed in 2020 with approximately $400 million total potential value for co-development and co-commercialization of BIIB122 (DNL151), an LRRK2 inhibitor for Parkinson's disease. The collaboration included upfront payment and potential milestones. In May 2026, the companies discontinued development of BIIB122 for idiopathic Parkinson's after Phase 2b LUMA trial failure, though Denali continues independent Phase 2a BEACON trial for LRRK2-associated Parkinson's.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Collaboration established in 2018 for co-development of neurodegenerative disease treatments including DNL593 (progranulin replacement therapy for frontotemporal dementia). Takeda terminated the partnership in April 2026 for strategic reasons unrelated to efficacy or safety, returning full rights to Denali. Phase 1/2 study results expected by end of 2026.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Partnership to develop RIPK1 inhibitors for conditions including Alzheimer's, ALS, and Multiple Sclerosis. Sanofi effectively ended the collaboration in January 2026 by deprioritizing eclitasertib, with Denali also having dropped its RIPK1 program earlier.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sarepta develops genetic medicines including gene therapies and antisense oligonucleotides for rare diseases, with a focus on Duchenne muscular dystrophy and other genetic neuromuscular conditions. Sarepta directly competes with Denali in the platform-based genetic medicine space for rare CNS and neuromuscular disorders.

TypeEmerging player
Description

REGENXBIO is a gene therapy company developing AAV-based treatments including for CNS indications, with proprietary NAV technology platform. REGENXBIO's AAV delivery approach directly competes with Denali's transferrin receptor BBB-crossing platform as alternative routes to brain delivery of genetic medicines.

TypeDirect peer
Description

Sage Therapeutics is a CNS specialty pharmaceutical company developing treatments for neurological conditions including postpartum depression (Zurzuvae) and epileptic encephalopathies. Sage directly competes with Denali in the CNS specialty pharma space with a similar focus on rare neurological indications.

TypeDirect peer
Description

Voyager Therapeutics develops gene therapies for CNS diseases using AAV vectors, with a particular focus on improving brain delivery of genetic medicines — directly overlapping with Denali's mission of delivering therapeutics across the BBB. Voyager represents a competing approach (viral vectors vs. transferrin receptor) to the same fundamental problem.

TypeDirect peer
Description

BioMarin is a direct peer as a rare disease-focused biotech with a portfolio of enzyme replacement and biologic therapies for lysosomal storage disorders and other genetic conditions. Both companies develop biologic therapies for small patient populations in genetic diseases, with comparable premium orphan drug pricing models and similar regulatory pathways.

TypeDirect peer
Description

Ionis is the leading antisense oligonucleotide (ASO) therapeutics company, developing treatments for neurological and rare diseases including SMA (Spinraza), ALS, and Huntington's. Ionis directly competes with Denali's OTV platform franchise, which uses oligonucleotides to modulate CNS gene expression, and shares the same mechanism class for many pipeline programs.

TypeDirect peer
Description

Wave Life Sciences is a direct peer developing stereopure antisense oligonucleotides for CNS diseases including Huntington's, ALS, and Duchenne muscular dystrophy. Wave directly competes with Denali's OTV platform in the ASO-for-CNS space and shares a similar focus on neurological genetic diseases.

TypeEmerging player
Description

uniQure is a gene therapy company developing AAV-based treatments for CNS and other rare diseases, including Huntington's disease. uniQure represents an alternative platform approach to delivering genetic medicines to the brain, overlapping with Denali's CNS gene therapy ambitions.

TypeBroad incumbent
Description

Eli Lilly is a broad incumbent in neurodegenerative and rare disease therapeutics, with major programs in Alzheimer's (Kisunla), Parkinson's, and rare diseases. Lilly's neuroscience franchise competes with Denali at the indication level (Alzheimer's, Parkinson's) despite operating at vastly larger scale and not specializing in BBB delivery.

TypeBroad incumbent
Description

Biogen is a broad incumbent in CNS therapeutics with established franchises in multiple sclerosis, spinal muscular atrophy (Spinraza), Alzheimer's (Aduhelm/Leqembi), and was a major Denali partner on BIIB122 for Parkinson's. Biogen operates at much larger scale across many CNS indications rather than specializing in BBB delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Denali Therapeutics

Biopharmaceuticals — Neurodegenerative and Rare Disease Therapeuticsdenalitherapeutics.com

Denali Therapeutics is a commercial-stage biopharmaceutical company developing therapeutics that cross the blood-brain barrier using its proprietary TransportVehicle platform, serving patients with neurodegenerative diseases and lysosomal storage disorders such as Hunter syndrome.

What Denali Therapeutics does

Denali Therapeutics is a clinical-stage and now commercial-stage biopharmaceutical company developing therapeutics that cross the blood-brain barrier to treat neurodegenerative diseases and lysosomal storage disorders. The company's proprietary TransportVehicle (TV) platform is a modular delivery technology using Transferrin Receptor targeting to deliver large molecule biotherapeutics — including enzymes, oligonucleotides, and antibodies — to the brain following systemic administration, achieving 10-30x greater brain exposure than conventional methods. In March 2026, the FDA granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier, for the treatment of neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. The company's pipeline extends the TV platform across multiple franchises, including DNL126 (Sanfilippo syndrome type A), DNL952 (Pompe disease), DNL593 (frontotemporal dementia), and DNL628 (Alzheimer's disease).

Denali's business model centers on commercial sales of AVLAYAH priced at $5,200 per 150mg vial with annual treatment costs of $270,000-$811,000 depending on patient weight — a ~60% premium over the Elaprase standard of care. The company targets an addressable population of approximately 400-500 US patients and ~2,000 globally, distributed through specialty pharmacies with patient support services. Non-dilutive capital sources include a $275M synthetic royalty agreement with Royalty Pharma (9.25% royalty on worldwide net sales) and a $195M sale of a Rare Pediatric Disease Priority Review Voucher. Equity financing has included a $500M private placement in February 2024 and a $200M public offering in December 2025, bringing cash and equivalents to approximately $1.05-1.17 billion.

Denali is headquartered in South San Francisco, California, with additional offices in Salt Lake City, Utah (manufacturing) and Zurich, Switzerland. The company is publicly traded on NASDAQ under the ticker DNLI with a market capitalization of approximately $4.05 billion as of June 2026, 251-500 employees, and 92.92% institutional ownership. Recent strategic setbacks include the discontinuation of BIIB122 with Biogen after the Phase 2b LUMA trial failed in idiopathic Parkinson's disease, and the termination of the DNL593 collaboration by Takeda, both of which have refocused the company on independent pipeline development.

Denali Therapeutics firmographics

Firmographics
Name
Denali Therapeutics
Legal name
Denali Therapeutics Inc.
Website
https://denalitherapeutics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Denali Therapeutics is a commercial-stage biopharmaceutical company developing therapeutics that cross the blood-brain barrier using its proprietary TransportVehicle platform, serving patients with neurodegenerative diseases and lysosomal storage disorders such as Hunter syndrome.
Ownership category
akta.pro rank

Denali Therapeutics industry classification

Industry
Product category
Biopharmaceuticals — Neurodegenerative and Rare Disease Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Blood-brain barrier delivery
  • Enzyme replacement therapy
  • Neurodegenerative disease therapeutics
  • Lysosomal storage disorder treatment
  • Biotherapeutic drug development

Where Denali Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Denali Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AVLAYAH Product Sales: Revenue from commercial sales of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome. Priced at $5,200 per 150mg vial with annual costs of $270,000-$811,000 depending on patient weight. Targeting approximately 400-500 US patients and ~2,000 globally.
  2. Royalty Revenue: Non-dilutive royalty funding arrangement with Royalty Pharma providing $275 million based on future net sales of tividenofusp alfa, with Royalty Pharma receiving 9.25% royalty on worldwide net sales
  3. Priority Review Voucher Sale: Sale of FDA Rare Pediatric Disease Priority Review Voucher earned from AVLAYAH approval for $195 million in June 2025

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPer-vial pricing for AVLAYAH enzyme replacement therapy

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Denali Therapeutics product offering

Product offering

Core offering

Denali Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes biotherapeutics capable of crossing the blood-brain barrier. Its FDA-approved product AVLAYAH (tividenofusp alfa-eknm) is an enzyme replacement therapy for the neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients, launched in March 2026 as the first FDA-approved biologic designed to cross the BBB. The company also maintains a clinical pipeline spanning Sanfilippo syndrome type A, Pompe disease, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, all built on its proprietary TransportVehicle (TV) platform.

Product overview

Denali Therapeutics is a biopharmaceutical company that has transitioned from R&D to commercial-stage operations with the FDA approval of AVLAYAH in March 2026. The company's core offering centers on its proprietary TransportVehicle (TV) platform, which enables biotherapeutics to cross the blood-brain barrier. The TV platform supports three franchise areas: Enzyme TransportVehicle (ETV) for lysosomal storage disorders, Oligonucleotide TransportVehicle (OTV) for CNS gene expression modulation, and Antibody TransportVehicle (ATV) for antibody delivery to the brain. The approved product AVLAYAH (tividenofusp alfa-eknm) is an enzyme replacement therapy for Hunter syndrome. The pipeline includes multiple candidates across lysosomal storage disorders, neurodegenerative diseases, and inflammatory conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • TransportVehicle™ (TV) Platform: Proprietary platform enabling delivery of enzymes, oligonucleotides and antibodies across the blood-brain barrier
  • Enzyme TransportVehicle™ (ETV)
  • Oligonucleotide TransportVehicle™ (OTV)
  • Antibody TransportVehicle™ (ATV)
  • AVLAYAH™ (tividenofusp alfa-eknm)

Products and services

  • AVLAYAH (tividenofusp alfa-eknm) FDA-approved enzyme replacement therapy for the neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. AVLAYAH uses Denali's proprietary TransportVehicle technology to cross the blood-brain barrier, addressing CNS symptoms that previous enzyme replacement therapies like Elaprase cannot treat. Priced at $5,200 per 150mg vial with annual costs of $270,000–$811,000 depending on patient weight.

Quantifiable outcome

  • 91% reduction in cerebrospinal fluid heparan sulfate levels after 24 weeks of treatment with AVLAYAH
  • +3 more outcomes

Companies that use Denali Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Denali Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Denali Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • BiogencoreStrategic or Co-development Partner · 1 March 2020Partnership formed in 2020 with approximately $400 million total potential value for co-development and co-commercialization of BIIB122 (DNL151), an LRRK2 inhibitor for Parkinson's disease. The collaboration included upfront payment and potential milestones. In May 2026, the companies discontinued development of BIIB122 for idiopathic Parkinson's after Phase 2b LUMA trial failure, though Denali continues independent Phase 2a BEACON trial for LRRK2-associated Parkinson's.
  • TakedacoreStrategic or Co-development Partner · 1 January 2018Collaboration established in 2018 for co-development of neurodegenerative disease treatments including DNL593 (progranulin replacement therapy for frontotemporal dementia). Takeda terminated the partnership in April 2026 for strategic reasons unrelated to efficacy or safety, returning full rights to Denali. Phase 1/2 study results expected by end of 2026.
  • SanofiminorStrategic or Co-development Partner · 1 January 2018Partnership to develop RIPK1 inhibitors for conditions including Alzheimer's, ALS, and Multiple Sclerosis. Sanofi effectively ended the collaboration in January 2026 by deprioritizing eclitasertib, with Denali also having dropped its RIPK1 program earlier.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Denali Therapeutics competitors and assessment

Company assessment

Direct peers

  • Sarepta Therapeutics: Sarepta develops genetic medicines including gene therapies and antisense oligonucleotides for rare diseases, with a focus on Duchenne muscular dystrophy and other genetic neuromuscular conditions. Sarepta directly competes with Denali in the platform-based genetic medicine space for rare CNS and neuromuscular disorders.
  • Sage Therapeutics: Sage Therapeutics is a CNS specialty pharmaceutical company developing treatments for neurological conditions including postpartum depression (Zurzuvae) and epileptic encephalopathies. Sage directly competes with Denali in the CNS specialty pharma space with a similar focus on rare neurological indications.
  • Voyager Therapeutics: Voyager Therapeutics develops gene therapies for CNS diseases using AAV vectors, with a particular focus on improving brain delivery of genetic medicines — directly overlapping with Denali's mission of delivering therapeutics across the BBB. Voyager represents a competing approach (viral vectors vs. transferrin receptor) to the same fundamental problem.
  • BioMarin Pharmaceutical: BioMarin is a direct peer as a rare disease-focused biotech with a portfolio of enzyme replacement and biologic therapies for lysosomal storage disorders and other genetic conditions. Both companies develop biologic therapies for small patient populations in genetic diseases, with comparable premium orphan drug pricing models and similar regulatory pathways.
  • Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide (ASO) therapeutics company, developing treatments for neurological and rare diseases including SMA (Spinraza), ALS, and Huntington's. Ionis directly competes with Denali's OTV platform franchise, which uses oligonucleotides to modulate CNS gene expression, and shares the same mechanism class for many pipeline programs.
  • Wave Life Sciences: Wave Life Sciences is a direct peer developing stereopure antisense oligonucleotides for CNS diseases including Huntington's, ALS, and Duchenne muscular dystrophy. Wave directly competes with Denali's OTV platform in the ASO-for-CNS space and shares a similar focus on neurological genetic diseases.

Emerging players

  • REGENXBIO: REGENXBIO is a gene therapy company developing AAV-based treatments including for CNS indications, with proprietary NAV technology platform. REGENXBIO's AAV delivery approach directly competes with Denali's transferrin receptor BBB-crossing platform as alternative routes to brain delivery of genetic medicines.
  • uniQure: uniQure is a gene therapy company developing AAV-based treatments for CNS and other rare diseases, including Huntington's disease. uniQure represents an alternative platform approach to delivering genetic medicines to the brain, overlapping with Denali's CNS gene therapy ambitions.

Broad incumbents

  • Eli Lilly: Eli Lilly is a broad incumbent in neurodegenerative and rare disease therapeutics, with major programs in Alzheimer's (Kisunla), Parkinson's, and rare diseases. Lilly's neuroscience franchise competes with Denali at the indication level (Alzheimer's, Parkinson's) despite operating at vastly larger scale and not specializing in BBB delivery.
  • Biogen: Biogen is a broad incumbent in CNS therapeutics with established franchises in multiple sclerosis, spinal muscular atrophy (Spinraza), Alzheimer's (Aduhelm/Leqembi), and was a major Denali partner on BIIB122 for Parkinson's. Biogen operates at much larger scale across many CNS indications rather than specializing in BBB delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Denali Therapeutics social profiles

Digital presence

Denali Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Denali Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Denali Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Denali Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Denali Therapeutics

What does Denali Therapeutics do?

Denali Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes biotherapeutics capable of crossing the blood-brain barrier. Its FDA-approved product AVLAYAH (tividenofusp alfa-eknm) is an enzyme replacement therapy for the neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients, launched in March 2026 as the first FDA-approved biologic designed to cross the BBB. The company also maintains a clinical pipeline spanning Sanfilippo syndrome type A, Pompe disease, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, all built on its proprietary TransportVehicle (TV) platform.

Is Denali Therapeutics a public or private company?

Denali Therapeutics is a public company. It is classified as public and is currently operating.

When was Denali Therapeutics founded?

Denali Therapeutics was founded in 2015. It employs 501 to 1,000 people.

Where is Denali Therapeutics based?

Denali Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Denali Therapeutics make money?

Three revenue lines are on record. AVLAYAH Product Sales are the primary driver. The others are royalty Revenue and priority Review Voucher Sale.

Who are Denali Therapeutics's main competitors?

Direct peers on record are Sarepta Therapeutics, Sage Therapeutics, Voyager Therapeutics, BioMarin Pharmaceutical, Ionis Pharmaceuticals and Wave Life Sciences. Emerging players are REGENXBIO and uniQure. Broad incumbents are Eli Lilly and Biogen.

Does Denali Therapeutics have an API?

No public API is recorded for Denali Therapeutics.

What industry is Denali Therapeutics in?

Denali Therapeutics's product category is Biopharmaceuticals — Neurodegenerative and Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comDenali Therapeutics at Jefferies Global Healthcare Conference: launch gainsDenali Therapeutics reported at Jefferies that AVLAYAH for Hunter syndrome exceeded internal expectations in its first two quarters, with Q4 2026 revenue guided at $30-32 million. The company expects AVLAYAH to surpass ELAPRASE's $700 million revenue if label expansion and international access succeed. A major 2027 pipeline includes Sanfilippo, FTD, and Alzheimer's data.American Banking and Market NewsDenali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones NearDenali Therapeutics reported $7.8 million in commercial revenue for AVLAYAH in Q2, with about 70% of commercial lives covered and 20 states having Medicaid coverage. The company targets roughly 375 of 500 eligible U.S. Hunter disease patients, aiming to switch 100% of them. It expects Q4 revenue of $30-32 million and plans a confirmatory trial completion in 2027.Defense WorldDenali Therapeutics Inc. $DNLI Position Boosted by Fisher Asset Management LLCFisher Asset Management boosted its Denali Therapeutics stake by 1.9% in Q3, buying 46,383 shares. Analysts have a consensus "Moderate Buy" rating with an average price target of $35.71. The company reported Q2 EPS of $0.37, beating estimates.Seeking AlphaDenali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptDenali Therapeutics reported strong progress on AVLAYAH launch, with 70% of commercial lives covered and 20 states on Medicaid. The drug generated $7.8 million in commercial revenue in the second quarter after launch. The company also previewed data readouts for other pipeline programs next year.TradingViewMorgan Stanley maintains Denali Therapeutics at Overweight, lowers price target to $37 from $42Morgan Stanley maintained Denali Therapeutics at Overweight and lowered its price target to $37 from $42, an 11.9% decrease. The target implies an upside of 95.9% from the Nov 12 close of $18.89. Recent analyst price targets range from $24 to $42.TradingViewDenali Therapeutics Inc. Stock 12‑Month Price Target Cut to $35.82, Implies 90% UpsideAnalysts' average price target for Denali Therapeutics fell from $36.12 to $35.82, implying about 90% upside from the Nov. 12 close. The consensus remains a Buy across 21 analysts, with 20 Buys, 1 Hold, and no Sells.Seeking AlphaDenali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)Denali Therapeutics is receiving a speculative Buy rating, with its DNL126 drug for Sanfilippo A expected to seek accelerated-approval BLA in 2027. The company plans to reuse its Avlayah commercial playbook almost one-for-one.MarketBeatDenali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones NearDenali Therapeutics is targeting all eligible U.S. patients for its Hunter disease treatment AVLAYAH, which generated $7.8 million in Q2 revenue. The company expects to switch 100% of the roughly 375 eligible patients, with confirmatory trial data expected in 2028. It also plans accelerated approval for its Sanfilippo program in 2027.Simply Wall StWill Profitable Quarter Change Denali Therapeutics Stock NarrativeDenali Therapeutics reported Q3 2026 revenue of $17.78 million and net income of $70.13 million, with EPS of $0.37. The company still posted a $185.87 million net loss for the first nine months of 2026. Q4 2026 net product revenue guidance of $30-32 million is the key near-term catalyst.